Chugai’s Satralizumab Wins FDA Breakthrough Therapy Status

Chugai Pharmaceutical said on December 19 that the US FDA has granted Breakthrough Therapy designation for its investigational humanized recycling anti-IL-6 receptor monoclonal antibody satralizumab, also known with the code SA237. The designation was given for the treatment of neuromyelitis...read more